The US Food and Drug Administration (FDA) has stated in its briefing document that Moderna’s experimental Covid-19 vaccine, mRNA-1273, is 94.1% effective in preventing symptomatic Covid-19.

This development comes ahead of a meeting by FDA advisers who will vote whether to recommend the grant of emergency approval for the vaccine in the US before a final FDA decision, Bloomberg reported.

The Moderna vaccine is based on SARS-CoV-2 spike glycoprotein (S) antigen encoded by RNA and formulated in lipid nanoparticles.

The proposed use of vaccine under an EUA is for active immunisation for Covid-19 prevention in adults.

Under the planned dosing regimen, two 100μg doses of the vaccine are to be given one month apart.

A safety data from an 11 November interim analysis of around 30,350 adults, who were randomly given the vaccine or placebo with a median of seven weeks of follow-up on receiving the second dose, showed a favourable safety profile.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Earlier this month, Moderna announced that the primary efficacy analysis data from the Phase III COVE study of mRNA-1273 indicated 100% vaccine efficacy against severe Covid-19.

The vaccines of Moderna and Pfizer are based on messenger RNA technology, which was earlier not used in inoculations.

In a separate development, Panama approved the emergency use of Pfizer and BioNtech’s vaccine.

Reuters quoted Panama Health Vice Minister Ivette Barrio as saying that the first batch of the dose could reach in the first quarter next year.

Furthermore, the European Medicines Agency (EMA) will meet on 21 December to analyse vaccine made by Pfizer and BioNtech. This meeting was initially scheduled as late as 29 December.

Last week, the US FDA advisory committee released a briefing document confirming safety and efficacy data of Pfizer and BioNTech’s Covid-19 vaccine candidate, BNT162b2.

The vaccine was later approved for emergency use against Covid-19 in individuals aged 16 years and above in the US.

Separately, the researchers from the University of Cambridge in the UK have found that remdesivir could be a highly effective antiviral against Covid-19 in a new single-patient study.

In the study, the vaccine was tested on a Covid-19 patient with a rare immune disorder and showed improvement in symptoms and the disappearance of the virus.